Doravirine injections were safe and long-lasting, but did not reach therapeutic levels
Top 5 HIV treatment stories at AIDS 2020
Overdose deaths have reduced survival gains among people with HIV in British Columbia
96 weeks results from two African studies confirm dolutegravir non-inferiority but highlight continued weight gain
Promising results for vesatolimod in monkeys and humans
Gene therapy or immunotherapy: which approach is more likely to deliver a cure for HIV?
“If we don’t include women in trials, we are not protecting women” – dolutegravir in pregnant women living with HIV
Depo Provera may worsen tenofovir-related bone loss in young women
Switching to Biktarvy maintains viral suppression in people aged 65 or over
